Medicinal glass is one of the widely used medicinal packaging materials in China. It can be divided into soda lime glass and borosilicate glass. Boron silicate glass is divided into low borosilicate, medium borosilicate and high borosilicate glass. According to the "China Pharmaceutical Glass Packaging Depth Survey and Investment Strategy Report (2019 Edition)", the current domestic pharmaceutical glass products are still dominated by low borosilicate glass and soda lime glass.
It is understood that low borosilicate glass is called "semi-neutral borosilicate medical glass", and its chemical stability is low. When a drug with a high pH value is contained, the alkaline substance in the glass is easily precipitated and affects the quality of the drug. Most countries have long since they are not used.
However, in China, most of the current medicinal glass is still low borosilicate glass. The total amount of medicinal glass in the whole year is about 300,000 tons, of which the amount of borosilicate used in 2018 is about 22,000 tons. 23,000 tons, according to the proportion, it is only about 7% to 8%.
As the pharmaceutical packaging industry upstream of the pharmaceutical industry's industrial chain, the market scale has maintained a high compound growth rate in the past five years. The Asia-Pacific market, which is dominated by China, has already surpassed Europe and approached North America in scale. However, behind the rapid growth, China's pharmaceutical packaging industry is large but not strong, and the overall value-added of the industry is not high. The enterprises are generally small in scale, low in technology level, single in product structure, and compared with mature markets in Europe and America in terms of personnel, equipment and management. There is still a big gap.
For China, why can't produce high-quality and high-qualification Zhongbo glass tubes, there is industry analysis, high cost has hindered the popularization of neutral medicinal glass in China. In addition, the stability of Zhongbo glass tube production is difficult to control. It also hindered the development of neutral medicinal glass to a certain extent.
But drugs are a special kind of commodity that is directly related to the health and safety of consumers. Pharmaceutical packaging materials can be directly contacted with drugs, and the quality of them will affect the safety of drugs, the stability of drugs and the sale of drugs. Accelerating the realization of China's upgrading from low borosilicate glass to borosilicate glass is essential.
The industry said that in line with the current Chinese policy and the concept of healthy China, pharmaceutical packaging is constantly upgrading, which will promote the upgrade of low borosilicate glass to borosilicate glass. According to industry predictions, in the next 5 to 10 years, 30%-40% of China's 300,000 tons of medicinal glass will be upgraded from low borosilicate glass to medium borosilicate glass.
From the implementation of the policy, the implementation of important industrial policies such as “injection consistency evaluation” and “association review” will affect the future pattern, and the upgrade of low boron to medium boron is still an irreversible trend. "In recent years, China is accelerating the promotion of consistency evaluation, related review and approval policies, etc., which will effectively promote the upgrading of pharmaceutical packaging materials following generic drugs, and the replacement process of neutral medicinal glass is expected to accelerate."
Taking Shandong Pharmaceutical Glass as an example, some research reports indicate that it is a domestic medicinal glass leader, benefiting from the strict market share brought by strict drug safety supervision, product upgrade revenue structure is continuously optimized, revenue growth is stable; scale and cost The advantages are significant, and the potential is continuously tapped. The profitability is rising steadily and the performance is growing steadily.
As for the performance of Shandong Pharmaceutical Glass in the past five years, it can be seen that the performance of Shandong Pharmaceutical Glass has shown steady growth. From 2014 to 2018, its operating income was 1.691 billion yuan, 1.723 billion yuan, 2.557 billion yuan, 2.33 billion yuan, 2.585 billion yuan, with year-on-year growth rates of 9.49%, 1.90%, 19.40%, 13.27%, 10.91%. The net profit of returning to the mother was 125 million yuan, 145 million yuan, 190 million yuan, 263 million yuan, and 358 million yuan, with year-on-year growth rates of 1.94%, 16.60%, 30.40%, 38.58%, and 36.33%, respectively.
It is understood that the current domestic pharmaceutical glass market is nearly 10 billion yuan, with an average annual growth rate of more than 10%. At present, there are more than 60 pharmaceutical glass production enterprises, mainly distributed in the Southwest, East China, North China and other regions. The domestic demand for main medicinal glass products (molded bottles, control bottles, ampoules) is about 80 billion pieces per year, of which about 15 billion are for molded bottles and controlled bottles, and nearly 40 billion for ampoules.
Panshi customized different quality specifications of the glass.
Panshi special industrial glass, tailored for your different quality of the glass.
Welcome sending your inquiry: Phone : +8617656208428 Email: firstname.lastname@example.org